AR082776A1 - Estabilizacion de hormona foliculo estimulante (fsh) - Google Patents
Estabilizacion de hormona foliculo estimulante (fsh)Info
- Publication number
- AR082776A1 AR082776A1 ARP110102766A ARP110102766A AR082776A1 AR 082776 A1 AR082776 A1 AR 082776A1 AR P110102766 A ARP110102766 A AR P110102766A AR P110102766 A ARP110102766 A AR P110102766A AR 082776 A1 AR082776 A1 AR 082776A1
- Authority
- AR
- Argentina
- Prior art keywords
- stabilization
- fsh
- folicle
- hormone
- stimulating
- Prior art date
Links
- 230000006641 stabilisation Effects 0.000 title abstract 3
- 238000011105 stabilization Methods 0.000 title abstract 3
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- -1 alkali metal cations Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 159000000001 potassium salts Chemical class 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Fats And Perfumes (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171428A EP2417982A1 (en) | 2010-07-30 | 2010-07-30 | Stabilization of gonadotropins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082776A1 true AR082776A1 (es) | 2013-01-09 |
Family
ID=43216624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102766A AR082776A1 (es) | 2010-07-30 | 2011-07-29 | Estabilizacion de hormona foliculo estimulante (fsh) |
Country Status (27)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| MX356383B (es) * | 2013-11-12 | 2018-05-24 | Cadila Healthcare Ltd | Formulación líquida de gonadotropina estabilizada con polietilenglicol. |
| CN105727260A (zh) * | 2016-02-03 | 2016-07-06 | 华侨大学 | 一种卵泡刺激素的长效制剂 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| FR3083089A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| CN111836616B (zh) | 2017-12-07 | 2024-01-16 | 阿道恰公司 | 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液 |
| BR112020011570A2 (pt) | 2017-12-07 | 2020-12-08 | Adocia | Solução injetável a um ph 7 compreendendo pelo menos uma insulina basal apresentando um pi entre 5,8 e 8,5 e um co-poliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos |
| FR3084584B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes |
| FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
| JP7425459B2 (ja) * | 2019-10-11 | 2024-01-31 | 株式会社シノテスト | 安定化されたｈｍｇｂ１含有溶液 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA61053C2 (en) | 1995-03-21 | 2003-11-17 | Applied Research Systems | Stable liquid pharmaceutical compositions, method for its production and delivery form |
| AU738176B2 (en) * | 1996-05-29 | 2001-09-13 | Delsitech Oy | Dissolvable oxides for biological applications |
| IL122732A0 (en) | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| KR20010083126A (ko) * | 1998-07-23 | 2001-08-31 | 피터 지. 스트링거 | 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법 |
| MXPA06011029A (es) * | 2004-04-07 | 2007-01-25 | Ares Trading Sa | Formulacion liquida de hormona del crecimiento. |
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| SI2249869T1 (sl) * | 2008-02-08 | 2012-01-31 | Biogenerix Ag | Tekoäśa formulacija fsh |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| CN101614748A (zh) * | 2008-06-25 | 2009-12-30 | 上海新波生物技术有限公司 | 促卵泡激素时间分辨免疫荧光分析法及试剂盒 |
| MX2011013898A (es) * | 2009-06-22 | 2012-05-22 | Amgen Inc | Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado. |
| RU2553375C2 (ru) * | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
-
2010
- 2010-07-30 EP EP10171428A patent/EP2417982A1/en not_active Withdrawn
-
2011
- 2011-07-21 JO JOP/2011/0231A patent/JO3229B1/ar active
- 2011-07-25 TW TW100126190A patent/TWI439283B/zh active
- 2011-07-28 RS RS20170265A patent/RS55772B1/sr unknown
- 2011-07-28 AU AU2011284702A patent/AU2011284702C1/en active Active
- 2011-07-28 HR HRP20170386TT patent/HRP20170386T1/hr unknown
- 2011-07-28 LT LTEP11736111.3T patent/LT2598160T/lt unknown
- 2011-07-28 CA CA2805864A patent/CA2805864A1/en active Pending
- 2011-07-28 MX MX2016010733A patent/MX356951B/es unknown
- 2011-07-28 KR KR1020187001203A patent/KR101991756B1/ko active Active
- 2011-07-28 SI SI201131132A patent/SI2598160T1/sl unknown
- 2011-07-28 NZ NZ606366A patent/NZ606366A/en unknown
- 2011-07-28 PL PL11736111T patent/PL2598160T3/pl unknown
- 2011-07-28 JP JP2013521146A patent/JP5860047B2/ja active Active
- 2011-07-28 PT PT117361113T patent/PT2598160T/pt unknown
- 2011-07-28 WO PCT/EP2011/062986 patent/WO2012013742A2/en not_active Ceased
- 2011-07-28 HU HUE11736111A patent/HUE033592T2/hu unknown
- 2011-07-28 RU RU2012157154/15A patent/RU2574012C2/ru active
- 2011-07-28 NZ NZ628962A patent/NZ628962A/en unknown
- 2011-07-28 US US13/704,771 patent/US8993732B2/en active Active
- 2011-07-28 EP EP11736111.3A patent/EP2598160B1/en active Active
- 2011-07-28 EP EP16195020.9A patent/EP3144010A1/en not_active Withdrawn
- 2011-07-28 KR KR1020137002504A patent/KR101820115B1/ko active Active
- 2011-07-28 ES ES11736111.3T patent/ES2623634T3/es active Active
- 2011-07-28 CN CN201180037221.0A patent/CN103052398B/zh active Active
- 2011-07-28 CN CN201510508334.4A patent/CN105106939A/zh active Pending
- 2011-07-28 BR BR112013002312-0A patent/BR112013002312B1/pt active IP Right Grant
- 2011-07-28 DK DK11736111.3T patent/DK2598160T3/en active
- 2011-07-28 MX MX2013000681A patent/MX341464B/es active IP Right Grant
- 2011-07-29 AR ARP110102766A patent/AR082776A1/es not_active Application Discontinuation
- 2011-07-30 SA SA114350786A patent/SA114350786B1/ar unknown
-
2012
- 2012-12-13 ZA ZA2012/09497A patent/ZA201209497B/en unknown
- 2012-12-24 IL IL223821A patent/IL223821A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,382 patent/US9463221B2/en active Active
- 2015-12-17 JP JP2015245748A patent/JP2016102127A/ja active Pending
-
2016
- 2016-09-06 US US15/257,402 patent/US20170216405A1/en not_active Abandoned
-
2017
- 2017-01-03 IL IL249920A patent/IL249920A0/en unknown
- 2017-11-02 JP JP2017212395A patent/JP6522711B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082776A1 (es) | Estabilizacion de hormona foliculo estimulante (fsh) | |
| PE20150200A1 (es) | Formulacion de anticuerpos | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| CR20140185A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
| GT201300123A (es) | Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-(2,3-d)-pirimidin-6-carboxilico y procesos para su elaboracion | |
| MX364155B (es) | Sulfonamidas como moduladores de canales de sodio. | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| AR083035A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA | |
| CO6640270A2 (es) | Morfolinopirimidad y su uso en terapia | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| BR112014011055A2 (pt) | novos derivados de [1,2,3]triazolo[4,5-d]pirimidina | |
| DOP2012000314A (es) | Compuestos, composiciones de tiocetato y metodos de uso | |
| HN2010000084A (es) | Derivados de sulfonamida | |
| ECSP10010433A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| DOP2013000130A (es) | Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2 | |
| BR112015000520A2 (pt) | agente de espessamento estável com lipase | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| UA111198C2 (uk) | Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази | |
| EA201491002A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| PE20150083A1 (es) | Formulacion de ibuprofeno inyectable | |
| MX372721B (es) | Ánalogos halogenados de agentes antifi-broticos. | |
| BR112015027394A2 (pt) | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |